ThirtyFiveBio
Peter Joyce is a seasoned biotechnology executive with extensive experience in research and leadership roles. As the CEO and Founder of Grey Wolf Therapeutics since February 2018, and as Founder & Advisor for both Pathios Therapeutics and ThirtyFiveBio since November 2018 and March 2021 respectively, Peter has played pivotal roles in advancing therapeutic innovations. Previous positions include Senior Research Scientist at Vertex Pharmaceuticals from December 2012 to February 2018 and Postdoctoral Research Fellow at the Medical Research Council's Mammalian Genetics Unit from September 2009 to December 2012, where Peter developed ALS models and fostered international collaborations. An early career as a Regulatory Advisor at Wyeth Pharmaceuticals further contributed to Peter's comprehensive industry knowledge. Peter holds a PhD in Biochemistry and Genetics and a BSc in Biochemistry, both from the University of Bristol.
This person is not in the org chart
This person is not in any teams
ThirtyFiveBio
ThirtyFiveBio is an early-stage drug discovery company that was established in 2021 by a team of experienced pharmaceutical industry professionals and biotech entrepreneurs. Based in Oxford, UK, the company is founded upon a deep understanding of the biology of GPR35. We are currently engaged in a fully enabled drug discovery program to identify novel small-molecule modulators of GPR35